McKesson MCK
McKesson is a wholesale distributor of pharmaceutical products and health solutions, acting as an intermediary between manufacturers and pharmacies, hospitals, and other providers, while also offering technology services and oncology specialization. McKesson shows solid financial health with low net debt (DN/EBITDA 0.94) and good cash conversion (96.19%), although its earnings growth is negative (-17.60%) and its operating margin is very thin (1.35%). The recent guidance raise is a positive catalyst that the market has partially priced in.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
McKesson is a wholesale distributor of pharmaceutical products and health solutions, acting as an intermediary between manufacturers and pharmacies, hospitals, and other providers, while also offering technology services and oncology specialization. McKesson shows solid financial health with low net debt (DN/EBITDA 0.94) and good cash conversion (96.19%), although its earnings growth is negative (-17.60%) and its operating margin is very thin (1.35%). The recent guidance raise is a positive catalyst that the market has partially priced in.
Score by category
| Category | Score |
|---|---|
| Financial health | 4.9 |
| Quality / Moat | 5.1 |
| Valuation | 5.7 |
| Growth | 4.0 |
| Dividend | 3.0 |
| Momentum | 7.2 |
| Risk & Context | 9.0 |
OVERALL SCORE: 5.6/10
Context and risks
The macro context (rates, oil, geopolitics) does not materially affect McKesson's pharmaceutical distribution business. Its net debt is low (DN/EBITDA 0.94) and its activity is defensive, with no direct exposure to the relevant macro factors.
News considered in the analysis
- McKesson (MCK) Lifted Its Guidance, Is The Stock Still 11% Undervalued? — La mejora de la guía es un hecho material que confirma la solidez operativa del negocio de distribución, aunque el mercado ya lo ha descontado parcialmente.
- AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? — Listículo comparativo genérico sin información nueva sobre McKesson.
- AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? — Listículo comparativo genérico sin información nueva sobre McKesson.
- AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? — Listículo comparativo genérico sin información nueva sobre McKesson.
- AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? — Listículo comparativo genérico sin información nueva sobre McKesson.
Verdict: Hold, with a positive bias. The guidance raise and solid cash generation offset weak earnings growth and a thin margin.
Main risk: The extremely low operating margin (1.35%) leaves McKesson vulnerable to any pricing pressure in its distribution business, which is its main source of revenue.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →